The Indian Competition Authority directs for the first time a divestiture of assets in a merger case (Sun Pharma / Ranbaxy)

Introduction The Competition Commission of India (“CCI”) for the first time has directed divestitures of assets, before granting its final approval, in a combination relating to merger of Ranbaxy Laboratories Limited (“Ranbaxy”) into Sun Pharmaceutical Industries Limited (“Sun Pharma”) (referred to as the “Transaction”) [1]. Sun Pharma and Ranbaxy are both pharmaceutical companies, engaged in the manufacture and marketing of branded generic products in various countries, including India. A notification was filed with the CCI under Section 6(2) of the Competition Act, 2002 (“Act”) read with The Competition Commission of India (Procedure in regard to the Transaction of Business relating to Combinations), 2011 (“Combination Regulations”), governing the merger control provisions in India. The Act

L'accès à cet article est réservé aux abonnés

Déjà abonné ? Identifiez-vous

L’accès à cet article est réservé aux abonnés.

Lire gratuitement un article

Vous pouvez lire cet article gratuitement en vous inscrivant.

 

Version PDF

Auteurs

  • Shardul Amarchand Mangaldas (Mumbai)
  • Economic Laws Practice (Mumbai)

Citation

Gauri Chhabra, Suhail Nathani, The Indian Competition Authority directs for the first time a divestiture of assets in a merger case (Sun Pharma / Ranbaxy), 5 décembre 2014, e-Competitions December 2014, Art. N° 70811

Visites 375

Tous les numéros

  • Latest News issue 
  • Tous les News issues
  • Latest Special issue 
  • Tous les Special issues